Treatment | Pneumonitis incidence (%) | Median duration of response (months) | References |
Atezolizumab 1200 mg every 3 weeks | 1.6 | 16.3 | Rittmeyer et al 38 |
Docetaxel 75 mg/m2 every 3 weeks | 0.3 | 6.2 | |
Atezolizumab 1200 mg every 3 weeks | 3.5 | 14.3 | Fehrenbacher et al 39 |
Docetaxel 75 mg/m2 every 3 weeks | 0.0 | 7.2 | |
Durvalumab 10 mg/kg every 2 weeks | 11.2 | NR | Antonia et al 40 |
Placebo | 5.1 | 13.8 | |
Nivolumab 3 mg/kg every 2 weeks | 2.3 | NR | Brahmer et al 13 |
Docetaxel 75 mg/m2 every 3 weeks | 0.0 | 8.4 | |
Nivolumab 3 mg/kg every 2 weeks | 3.8 | 17.2 | Borghaei et al 41 |
Docetaxel 75 mg/m2 every 3 weeks | 0.7 | 5.6 | |
Pembrolizumab 200 mg every 3 weeks | 8.4 | NR | Reck et al 1 |
Chemotherapy | 1.3 | 6.3 | |
Pembrolizumab 2 mg/kg every 3 weeks | 6.2 | NR | Herbst et al 2 |
Pembrolizumab 10 mg/kg every 3 weeks | 5.5 | NR | |
Ipilimumab + chemotherapy | 0.5 | 5.7 | Govindan et al 42 |
Chemotherapy + placebo | 1.1 | 4.7 | |
Pembrolizumab + chemotherapy | 6.8 | NR | Langer et al 43 |
Chemotherapy | 0.0 | NR | |
Nivolumab 1 + ipilimumab 3 | 4.9 | 7.7 | Antonia et al 26 |
Nivolumab 3 + ipilimumab 1 | 9.2 | 4.4 | |
Nivolumab | 4.1 | NR |
NR, not reached.